Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases
Chunmei Wang, Qinqin Wang, Bingyuan Ji, et al.
Frontiers in Molecular Neuroscience (2018) Vol. 11
Open Access | Times Cited: 163

Showing 1-25 of 163 citing articles:

Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder
Russell Rosenberg, Patricia Murphy, Gary Zammit, et al.
JAMA Network Open (2019) Vol. 2, Iss. 12, pp. e1918254-e1918254
Open Access | Times Cited: 340
The Orexin/Hypocretin System, the Peptidergic Regulator of Vigilance, Orchestrates Adaptation to Stress
Miklós Jászberényi, Balázs Thurzó, Zsolt Bagosi, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 448-448
Open Access | Times Cited: 22
Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2
Mikko Kärppä, Jane Yardley, Kate Pinner, et al.
SLEEP (2020) Vol. 43, Iss. 9
Open Access | Times Cited: 127
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Eating disorders in narcolepsy type 1: Evidence from a cross‐sectional Italian study
Valentina Baldini, Noemi Venezia, Anna Iriti, et al.
Journal of Sleep Research (2024) Vol. 33, Iss. 5
Open Access | Times Cited: 11
Lemborexant: First Approval
Lesley J. Scott
Drugs (2020) Vol. 80, Iss. 4, pp. 425-432
Closed Access | Times Cited: 62
Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence
Kelly E. Dunn, Andrew S. Huhn, Cecilia L. Bergeria, et al.
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 371, Iss. 2, pp. 422-452
Open Access | Times Cited: 56
Drug Discovery and Development Targeting Dementia
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 151-151
Open Access | Times Cited: 20
Orexin receptor antagonists in the pathophysiology and treatment of sleep disorders and epilepsy
Mohammad Sheibani, Maryam Shayan, Mina Khalilzadeh, et al.
Neuropeptides (2023) Vol. 99, pp. 102335-102335
Closed Access | Times Cited: 18
Orexins/Hypocretins: Key Regulators of Energy Homeostasis
Edward Milbank, Miguel López
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 47
Differential Roles of Each Orexin Receptor Signaling in Obesity
Miyo Kakizaki, Yousuke Tsuneoka, Kenkichi Takase, et al.
iScience (2019) Vol. 20, pp. 1-13
Open Access | Times Cited: 46
Structure-based development of a subtype-selective orexin 1 receptor antagonist
Jan Hellmann, Matthäus Drabek, Jie Yin, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 30, pp. 18059-18067
Open Access | Times Cited: 46
The Important Role of Adiponectin and Orexin-A, Two Key Proteins Improving Healthy Status: Focus on Physical Activity
Rita Polito, Vincenzo Monda, Ersilia Nigro, et al.
Frontiers in Physiology (2020) Vol. 11
Open Access | Times Cited: 42
Synthetic Approaches to the New Drugs Approved during 2019
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 7, pp. 3604-3657
Closed Access | Times Cited: 36
Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder
Margaret Moline, Gary Zammit, Jocelyn Y. Cheng, et al.
Journal of Clinical Sleep Medicine (2021) Vol. 17, Iss. 6, pp. 1167-1174
Open Access | Times Cited: 33
Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities
Matteo Carpi, Laura Palagini, Mariana Fernandes, et al.
Neuropharmacology (2023) Vol. 245, pp. 109815-109815
Open Access | Times Cited: 15
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Identifying novel gene dysregulation associated with opioid overdose death: A meta-analysis of differential gene expression in human prefrontal cortex
Javan K. Carter, Bryan C. Quach, Caryn Willis, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
Pain-Insomnia-Depression Syndrome: Triangular Relationships, Pathobiological Correlations, Current Treatment Modalities, and Future Direction
Murtaza Haidary, Shamim Arif, Dawood Hossaini, et al.
Pain and Therapy (2024) Vol. 13, Iss. 4, pp. 733-744
Open Access | Times Cited: 5
Seltorexant for major depressive disorder
K.L. Valentino, Kayla M. Teopiz, Sabrina Wong, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
The involvement of orexin-1 receptors in modulation of feeding and anxiety-like behavior in rats with complete Freund’s adjuvant-induced temporomandibular joint disorder
Mojtaba Hosaini, Mehdi Abbasnejad, Razieh Kooshki, et al.
Odontology (2025)
Open Access
Role of OX/OXR cascade in insomnia and sleep deprivation link Alzheimer’s disease and Parkinson’s disease: Therapeutic avenue of Dual OXR Antagonist (DORA)
Siva Prasad Panda, Suman Sinha, Adarsh Kesharwani, et al.
Biochemical Pharmacology (2025), pp. 116794-116794
Closed Access
Computational Analysis of the Fully Activated Orexin Receptor 2 across Various Thermodynamic Ensembles with Surface Tension Monitoring and Markov State Modeling
Rafael Doležal
The Journal of Physical Chemistry B (2025)
Closed Access
Alzheimer’s disease with depression: clinical characteristics and potential mechanisms involving orexin and brain atrophy
Jing Li, Teng-hong Lian, Jinghui Li, et al.
Translational Psychiatry (2025) Vol. 15, Iss. 1
Open Access
GPCR drug discovery: new agents, targets and indications
José A. Lorente, Aleksandr V. Sokolov, Gavin Ferguson, et al.
Nature Reviews Drug Discovery (2025)
Closed Access
Page 1 - Next Page

Scroll to top